What diseases can Troxerutine be used to treat

Oral administration of Troxerutine is mainly from the gastrointestinal tract. The peak time (Cmax) is 1 to 6 hours, the plasma protein binding rate is about 30%, and the elimination half-life (t1/2β) is 10 to 25 hours. There may be intestinal hepatic circulation and metabolites 70. % excreted with feces.
Troxerutine is suitable for cerebral thrombosis and cerebral embolism caused by hemiplegia, aphasia and premature myocardial infarction syndrome, arteriosclerosis, central retinitis, thrombophlebitis, varicose veins, edema caused by increased vascular permeability.
Troxerutine is indicated for hemiplegia, aphasia, arteriosclerosis, preinfarction syndrome, thrombophlebitis, varicose veins, chronic venous insufficiency, central retinitis, diabetic retinitis, and increased vascular permeability caused by cerebral thrombosis Caused by edema, etc. The clinical application of Troxerutine shows that it has a wide range of applications and good curative effect, especially for the treatment of occlusive cerebrovascular disease.